--- schema_version: "secwatch.filing_event.v1" accession: "0001326190-23-000040" form_type: "8-K" ticker: "ALT" cik: "0001326190" company_name: "Altimmune, Inc." filed_at: "2023-09-28T23:59:59+00:00" generated_at: "2026-06-10T07:28:51.085856+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.25 calibrated_materiality_score: 0.15 confidence: "high" source: SEC EDGAR --- # Altimmune 2023 annual meeting results: all director nominees elected, say-on-pay approved ## Summary - All 9 director nominees elected; highest vote for was 21.9M, lowest 19.4M. - Say-on-pay advisory vote passed: 16.8M for, 5.2M against, 12.4M broker non-votes. - Stockholders selected 1-year frequency for future say-on-pay votes (21.6M for 1-year). - Ernst & Young ratified as auditor for FY2023 with 34.3M for, 153K against. - Adjournment proposal authorized with 27.7M for vs 6.7M against. ## SEC filing metadata - accession: 0001326190-23-000040 - form_type: 8-K - ticker: ALT - cik: 0001326190 - company_name: Altimmune, Inc. - filed_at: 2023-09-28T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.25 - calibrated_materiality_score: 0.15 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/alt-20230928x8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001326190-23-000040 - JSON: https://secwatch.observer/filing/0001326190-23-000040.json - Plain text: https://secwatch.observer/filing/0001326190-23-000040.txt ## Key facts - Shareholder Votes Altimmune, Inc. shareholders approved Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies at the 2023-09-28 meeting. - Outcome: passed - Meeting: 2023-09-28 source text: Proposal No. 5 : Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 27,712,554 ​ 6,744,992 104,432 evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm - Shareholder Votes Altimmune, Inc. shareholders approved Election of Directors at the 2023-09-28 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-09-28 source text: Proposal No. 1 : Election of Directors. The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Broker Director ​ For ​ Withhold ​ Non-Votes Mitchel Sayare, Ph.D., Chairman ​ 21,844,990 316,470 12,400,518 Vipin K. Garg, Ph.D. ​ 21,885,151 276,309 12,400,518 David J. Drutz, M.D. ​ 19,880,376 2,281,084 12,400,518 John M. Gill ​ 21,588,792 572,668 12,400,518 Philip L. Hodges ​ 21,810,125 351,335 12,400,518 Diane Jorkasky, M.D. ​ 21,824,133 337,327 12,400,518 Wayne Pisano ​ 19,385,875 2,775,585 12,400,518 Klaus O. Schafer, M.D., MPH 21,823,016 338,444 12,400,518 Catherine Sohn, Pharm D 21,912,287 249,173 12,400,518 evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm - Shareholder Votes Altimmune, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-09-28 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-09-28 source text: Proposal No. 2 : Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023. The results were as follows: ​ ​ ​ ​ ​ For ​ Against ​ Abstain 34,318,768 ​ 153,149 90,061 evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm - Shareholder Votes Altimmune, Inc. shareholders approved Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-09-28 source text: Proposal No. 3 : Advisory vote on the Compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ For ​ Against ​ Abstain ​ Broker Non-Votes 16,834,432 ​ 5,221,648 ​ 105,380 12,400,518 evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm - Shareholder Votes Altimmune, Inc. shareholders approved Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules at the 2023-09-28 meeting. - Proposal: say on pay frequency - Outcome: passed - Meeting: 2023-09-28 source text: Proposal No. 4 : Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC's compensation rules (referred to as the "frequency of say-on-pay" proposal). The results were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 1 Year ​ 2 Years ​ 3 Years ​ Abstain ​ Broker Non-Votes 21,595,590 ​ 80,595 352,096 133,179 12,400,518 evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000040/0001326190-23-000040-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.